All In Biotech

NDA 022327 · Perrigo Pharma Intl

Prevacid 24 Hr

Lansoprazole · Oral

Last checked: Nov 20, 2026Latest source record: Dec 29, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

May 18, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

288

83 Phase 3, 12 recruiting

FAERS reports

125,091

115,872 serious, 15,413 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PREVACID 24 HR · LANSOPRAZOLE 15MG · CAPSULE, DELAYED REL PELLETS, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Lansoprazole" as an intervention, any sponsor and status, largest first.

All 288 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease17,847
  • acute kidney injury11,658
  • renal failure7,773
  • diarrhoea6,776
  • renal injury6,174
  • dyspnoea6,079
  • off label use6,074
  • nausea5,838
  • end stage renal disease5,666
  • fatigue5,394
  • vomiting5,323
  • malaise4,848

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,299
20051,407
20061,111
20071,295
20081,663
20091,691
20101,934
20112,729
20123,421
20132,970
20143,516
20154,953
20166,295
20175,665
201815,384
201917,278
20208,898
20217,878
20227,149
20237,650
20248,173
20257,450
20265,281

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 932 on PubMed

Sponsor: Perrigo Pharma Intl

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.